keyword
MENU ▼
Read by QxMD icon Read
search

Namenda

keyword
https://www.readbyqxmd.com/read/25979127/discontinuation-of-memantine-standard-release-and-its-impact-on-patient-therapy
#1
Taryn Mondiello, Sum Lam
The recently announced discontinuation of Namenda (memantine HCl) and consequent shortage of Namenda XR (memantine HCl extended-release) is a matter that affects physicians, patients with Alzheimer's disease, caregivers, and consultant pharmacists. The manufacturer's announcement to discontinue standard-release product came eight months after the extended-release formulation became available in June 2013. The manufacturer planned to discontinue the standard-release tablets to focus on XR capsules by August 2014, giving patients and their caregivers-who prefer immediate-release formulations-no other options except the oral solution formulation...
May 2015: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/24389031/the-multi-functional-drug-tropisetron-binds-app-and-normalizes-cognition-in-a-murine-alzheimer-s-model
#2
Patricia Spilman, Olivier Descamps, Olivia Gorostiza, Clare Peters-Libeu, Karen S Poksay, Alexander Matalis, Jesus Campagna, Alexander Patent, Rammohan Rao, Varghese John, Dale E Bredesen
Tropisetron was identified in a screen for candidates that increase the ratio of the trophic, neurite-extending peptide sAPPα to the anti-trophic, neurite-retractive peptide Aβ, thus reversing this imbalance in Alzheimer's disease (AD). We describe here a hierarchical screening approach to identify such drug candidates, moving from cell lines to primary mouse hippocampal neuronal cultures to in vivo studies. By screening a clinical compound library in the primary assay using CHO-7W cells stably transfected with human APPwt, we identified tropisetron as a candidate that consistently increased sAPPα...
March 10, 2014: Brain Research
https://www.readbyqxmd.com/read/23621892/the-impact-of-medicare-prescription-drug-coverage-on-the-use-of-antidementia-drugs
#3
Nicole R Fowler, Yi-Fan Chen, Christiana A Thurton, Aiju Men, Eric G Rodriguez, Julie M Donohue
BACKGROUND: Cholinesterase inhibitors and memantine are prescribed to slow the progression dementia. Although the efficacy of these drugs has been demonstrated, their effectiveness, from the perspective of patients and caregivers, has been questioned. Little is known about whether the demand for cholinesterase inhibitors and memantine are sensitive to out-of-pocket cost. Using the 2006 implementation of Medicare Part D as a natural experiment, this study examines the impact of changes in drug coverage on use of cholinesterase inhibitors and memantine by comparing use before and after Medicare Part D implementation among older adults who did and did not experience a change in coverage...
2013: BMC Geriatrics
https://www.readbyqxmd.com/read/23583234/vitamin-e-and-memantine-in-alzheimer-s-disease-clinical-trial-methods-and-baseline-data
#4
RANDOMIZED CONTROLLED TRIAL
Maurice W Dysken, Peter D Guarino, Julia E Vertrees, Sanjay Asthana, Mary Sano, Maria Llorente, Muralidhar Pallaki, Susan Love, Gerard D Schellenberg, J Riley McCarten, Julie Malphurs, Susana Prieto, Peijun Chen, David J Loreck, Sara Carney, George Trapp, Rajbir S Bakshi, Jacobo E Mintzer, Judith L Heidebrink, Ana Vidal-Cardona, Lillian M Arroyo, Angel R Cruz, Neil W Kowall, Mohit P Chopra, Suzanne Craft, Stephen Thielke, Carolyn L Turvey, Catherine Woodman, Kimberly A Monnell, Kimberly Gordon, Julie Tomaska, Govind Vatassery
BACKGROUND: Alzheimer's disease (AD) has been associated with both oxidative stress and excessive glutamate activity. A clinical trial was designed to compare the effectiveness of (i) alpha-tocopherol, a vitamin E antioxidant; (ii) memantine (Namenda), an N-methyl-D-aspartate antagonist; (iii) their combination; and (iv) placebo in delaying clinical progression in AD. METHODS: The Veterans Affairs Cooperative Studies Program initiated a multicenter, randomized, double-blind, placebo-controlled trial in August 2007, with enrollment through March 2012 and follow-up continuing through September 2012...
January 2014: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/23421676/key-binding-interactions-for-memantine-in-the-nmda-receptor
#5
Walrati Limapichat, Wesley Y Yu, Emma Branigan, Henry A Lester, Dennis A Dougherty
Memantine (Namenda) is prescribed as a treatment for moderate to severe Alzheimer's Disease. Memantine functions by blocking the NMDA receptor, but the key binding interactions between drug and receptor are not fully elucidated. To determine key binding interactions of memantine, we made side-by-side comparisons of IC(50) for memantine and amantadine, a structurally related drug, in the GluN1/GluN2B NMDA receptor. We identified hydrophobic binding pockets for the two methyl groups on memantine formed by the residues A645 and A644 on the third transmembrane helices of GluN1 and GluN2B, respectively...
February 20, 2013: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/21875407/n-methyl-d-aspartate-nmda-receptor-antagonists-and-memantine-treatment-for-alzheimer-s-disease-vascular-dementia-and-parkinson-s-disease
#6
REVIEW
David Olivares, Varun K Deshpande, Ying Shi, Debomoy K Lahiri, Nigel H Greig, Jack T Rogers, Xudong Huang
Memantine, a partial antagonist of N-methyl-D-aspartate receptor (NMDAR), approved for moderate to severe Alzheimer's disease (AD) treatment within the U.S. and Europe under brand name Namenda (Forest), Axura and Akatinol (Merz), and Ebixa and Abixa (Lundbeck), may have potential in alleviating additional neurological conditions, such as vascular dementia (VD) and Parkinson's disease (PD). In various animal models, memantine has been reported to be a neuroprotective agent that positively impacts both neurodegenerative and vascular processes...
July 2012: Current Alzheimer Research
https://www.readbyqxmd.com/read/20705029/namenda
#7
Benjamin Yang
No abstract text is available yet for this article.
December 2003: Discovery Medicine
https://www.readbyqxmd.com/read/20349884/drug-therapies-for-cognitive-impairment-and-dementia
#8
Robert H Howland
Drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease include acetylcholinesterase inhibitor drugs (tacrine [Cognex®], donepezil [Aricept®], rivastigmine [Exelon®, Exelon Patch®], and galantamine [Reminyl®, Razadyne®]) and glutamate-modulating drugs (memantine [Namenda®]). They do not halt the underlying degenerative process but can slow disease progression. Piracetam is a nonprescription noot ropic drug designated by the FDA as an orphan drug for myoclonic seizures...
April 2010: Journal of Psychosocial Nursing and Mental Health Services
https://www.readbyqxmd.com/read/20104942/spotlight-on-memantine-in-moderate-to-severe-alzheimer-s-disease
#9
Kate McKeage
Memantine (Axura, Ebixa, Namenda) is an uncompetitive, moderate-affinity NMDA receptor antagonist that is indicated for the treatment of moderate to severe Alzheimer's disease. In well designed trials in patients with moderate to severe Alzheimer's disease, oral memantine monotherapy improved outcomes in the area of functional ability more than placebo in one trial, but in a second trial, treatment differences did not reach significance. Memantine has a distinct mode of action compared with that of acetylcholinesterase (AChE) inhibitors, and in a well designed study, combination therapy with memantine plus donepezil improved outcomes more than donepezil plus placebo in all four domains (function, cognition, behaviour and global change)...
February 1, 2010: Drugs & Aging
https://www.readbyqxmd.com/read/20013176/nanoparticle-and-iron-chelators-as-a-potential-novel-alzheimer-therapy
#10
Gang Liu, Ping Men, George Perry, Mark A Smith
Current therapies for Alzheimer disease (AD) such as the acetylcholinesterase inhibitors and the latest NMDA receptor inhibitor, Namenda, provide moderate symptomatic delay at various stages of the disease, but do not arrest the disease progression or bring in meaningful remission. New approaches to the disease management are urgently needed. Although the etiology of AD is largely unknown, oxidative damage mediated by metals is likely a significant contributor since metals such as iron, aluminum, zinc, and copper are dysregulated and/or increased in AD brain tissue and create a pro-oxidative environment...
2010: Methods in Molecular Biology
https://www.readbyqxmd.com/read/19291500/memantine-namenda-forest-pharmaceuticals
#11
Marian W Roman
No abstract text is available yet for this article.
March 2009: Issues in Mental Health Nursing
https://www.readbyqxmd.com/read/19196860/memantine-namenda-for-neuropathic-pain
#12
REVIEW
Mailien Rogers, Atif Rasheed, Abdolali Moradimehr, Steven J Baumrucker
Neuropathic pain is common in the palliative care population; unless adequately treated, the pain can lead to chronic anxiety, depression, and social impairment. Many treatments have been proposed for neuropathic pain; however, it remains underdiagnosed, under-treated, and often requires long-term therapy with risk of adverse effects. Memantine (Namenda), an N-Methyl, D-aspartate receptor inhibitor currently marketed for the treatment of dementia, has been proposed as a medication for the treatment of neuropathic pain for its mechanism, safety, lack of serious adverse effects, and relatively rapid onset of action...
February 2009: American Journal of Hospice & Palliative Care
https://www.readbyqxmd.com/read/17661541/pilot-trial-of-memantine-in-the-treatment-of-posttraumatic-stress-disorder
#13
RANDOMIZED CONTROLLED TRIAL
Matthew A Battista, Robert Hierholzer, Hani Raoul Khouzam, Alycia Barlow, Siobhan O'Toole
This multiple case series was initially designed as a prospective, open-label, 12-week trial investigation evaluating memantine (Namenda) for the treatment of psychiatric and cognitive symptoms associated with PTSD. In a selected, small sample of individuals (n = 4) with combat PTSD, treatment with memantine produced consistent improvement on a delayed recall measure of memory, variable reduction of depressive symptoms, and variable reduction in hyperarousal symptoms. These data suggest potential positive treatment outcomes, both cognitively and psychiatrically, and provide rationale for future double-blind, placebo-controlled studies of memantine in PTSD...
2007: Psychiatry
https://www.readbyqxmd.com/read/17555649/postmortem-memantine-concentrations
#14
Nichole Bynum, Justin Poklis, Diana Garside, Ruth Winecker
Postmortem fluid and tissue concentrations of memantine (Namenda), a drug recently approved for the treatment of Alzheimer's Disease by the FDA, are reported in a suspicious death. In addition, memantine concentrations considered to be incidental findings in three other cases are included to aid in the interpretation in future toxicological investigations. Memantine was extracted from biological samples by a standard liquid-liquid basic drug method followed by analysis utilizing a gas chromatograph-mass spectrometer operated in SIM mode...
May 2007: Journal of Analytical Toxicology
https://www.readbyqxmd.com/read/17516724/cost-effectiveness-of-memantine-in-moderately-severe-to-severe-alzheimer-s-disease-a-markov-model-in-finland
#15
Clément François, Harri Sintonen, Raimo Sulkava, Benoît Rive
BACKGROUND: In patients with moderately severe to severe Alzheimer's disease, the N-methyl-D-aspartate (NMDA) antagonist memantine has been shown to improve outcomes and to be associated with reductions in resource utilisation and total healthcare costs relative to no pharmacological intervention after 28 weeks in phase III clinical and pharmacoeconomic studies. However, the longer term cost implications of treatment with memantine are not known. OBJECTIVE: To evaluate the effect of treatment with memantine in patients with moderately severe to severe Alzheimer's disease on resource use and on cost and patient outcomes in Finland over a 5-year time horizon...
2004: Clinical Drug Investigation
https://www.readbyqxmd.com/read/17251419/abeta-oligomer-induced-aberrations-in-synapse-composition-shape-and-density-provide-a-molecular-basis-for-loss-of-connectivity-in-alzheimer-s-disease
#16
COMPARATIVE STUDY
Pascale N Lacor, Maria C Buniel, Paul W Furlow, Antonio Sanz Clemente, Pauline T Velasco, Margaret Wood, Kirsten L Viola, William L Klein
The basis for memory loss in early Alzheimer's disease (AD) seems likely to involve synaptic damage caused by soluble Abeta-derived oligomers (ADDLs). ADDLs have been shown to build up in the brain and CSF of AD patients and are known to interfere with mechanisms of synaptic plasticity, acting as gain-of-function ligands that attach to synapses. Because of the correlation between AD dementia and synaptic degeneration, we investigated here the ability of ADDLs to affect synapse composition, structure, and abundance...
January 24, 2007: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/17119537/preclinical-investigation-of-the-functional-effects-of-memantine-and-memantine-combined-with-galantamine-or-donepezil
#17
Diana S Woodruff-Pak, Michael J Tobia, Xilu Jiao, Kevin D Beck, Richard J Servatius
Combinations of drugs approved to treat Alzheimer's disease (AD) were tested in older rabbits with delay eyeblink classical conditioning, a form of associative learning severely impaired in AD. In Experiment 1 (n=49 rabbits), low doses (0.1, 0.5, 1.0, and 0.0 (vehicle) mg/kg) of memantine (Namenda) were tested. These three doses neither improved nor impaired acquisition at a statistically significant level. The 0.5 mg/kg dose had the greatest effect numerically and did not cause sensitization or habituation in explicitly unpaired controls...
June 2007: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/17112636/donepezil-markedly-potentiates-memantine-neurotoxicity-in-the-adult-rat-brain
#18
Catherine E Creeley, David F Wozniak, Anthony Nardi, Nuri B Farber, John W Olney
The NMDA antagonist, memantine (Namenda), and the cholinesterase inhibitor, donepezil (Aricept), are currently being used widely, either individually or in combination, for treatment of Alzheimer's disease (AD). NMDA antagonists have both neuroprotective and neurotoxic properties; the latter is augmented by drugs, such as pilocarpine, that increase cholinergic activity. Whether donepezil, by increasing cholinergic activity, might augment memantine's neurotoxic potential has not been investigated. In the present study, we determined that a dose of memantine (20mg/kg, i...
February 2008: Neurobiology of Aging
https://www.readbyqxmd.com/read/16906789/memantine-a-review-of-its-use-in-alzheimer-s-disease
#19
REVIEW
Dean M Robinson, Gillian M Keating
Memantine (Ebixa, Axura, Namenda, Akatinol) is a moderate-affinity, uncompetitive, voltage-dependent, NMDA-receptor antagonist with fast on/off kinetics that inhibits excessive calcium influx induced by chronic overstimulation of the NMDA receptor. Memantine is approved in the US and the EU for the treatment of patients with moderate to severe dementia of the Alzheimer's type. In well designed clinical trials, oral memantine, as monotherapy or in addition to a stable dose of acetylcholinesterase inhibitors, was well tolerated during the treatment of mild to severe Alzheimer's disease for up to 52 weeks...
2006: Drugs
https://www.readbyqxmd.com/read/16472162/brain-inflammation-cholesterol-and-glutamate-as-interconnected-participants-in-the-pathology-of-alzheimer-s-disease
#20
REVIEW
G E Ringheim, A M Szczepanik
Alzheimer's disease (AD) represents one of the most common ailments afflicting the rapidly growing elderly segment of today's population. Despite the vast amount of effort expended in developing a cure, currently approved drugs address only cognitive symptoms that, although important for improving a patient's daily living standard, do not provide a significant delay or halt to disease progression. Early reports that individuals taking anti-inflammatory medications reduce their risk of developing AD has led to the "inflammation hypothesis" of AD and the subsequent testing of these drugs in the clinic...
2006: Current Pharmaceutical Design
keyword
keyword
48725
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"